DENVER–(BUSINESS WIRE)–Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce the closing of its previously-announced bought-deal public offering led by Canaccord Genuity Corp.


Previous articlePsychedelic Business News Spotlight: February 12, 2021
Next articleWhy The Future of The Psychedelic Industry Could Be In The Hands of Retail Investors